CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? ............ 560
M. Ladanyi
Commentary on Cheung et al., p. 608

PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic ............ 562
D.A. Fruman and C. Rommel

Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence ............ 573

Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs .......... 580

Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.
Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas


Précis: Dedifferentiated liposarcomas harbor recurring HDACI mutations and exhibit aberrant methylomes, suggesting that epigenetic therapies may be effective in these tumors.

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers


Précis: Overexpression of the CRKL adaptor protein activates oncogenic signaling pathways and promotes drug resistance in NSCLC.

Correction

Correction: Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium

Correction: Forty Years of Translational Cancer Research

Correction: Drugs, Diagnostic Tests Approved Quickly

Acknowledgment to Reviewers

For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews. Online-only News stories include the following:

- HDAC Inhibitors Show Benefits in Breast Cancer
- Phenotypic Profiling Identifies Novel Anticancer Drugs
- Automated Pathology Gives Accurate Predictions
- Triple-Acting Drug Boosts Prostate Cancer Survival
- Analyzing Intact Proteins with Mass Spectrometry
- FDA Pulls Approval for Avastin in Breast Cancer

ON THE COVER

Juergens and colleagues present results from a phase I/II trial showing that combined epigenetic therapy with azacitidine and entinostat can elicit objective responses, including one complete and one partial response, in refractory metastatic non–small cell lung cancer (NSCLC). A decreased methylation signature in response to treatment was associated with longer overall and progression-free survival, indicative of on-target epigenetic effects. Furthermore, several patients had objective responses to subsequent anticancer therapies. This combination epigenetic therapy may therefore be effective in reversing the epigenetic mechanisms driving the progression and resistance of NSCLC. For details, please see the article by Juergens and colleagues on page 598.